Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Medicus Pharma Ltd ( (MDCX) ) just unveiled an announcement.
Medicus Pharma Ltd. has successfully closed a $4.2 million Tier II Regulation A offering, which will support their Phase 2 clinical trial for a novel skinpatch treatment for basal cell carcinoma. The funds may also be used to expand trials to other skin diseases, enhancing the company’s research capabilities and potentially strengthening its market position in dermatological treatments.
More about Medicus Pharma Ltd
Medicus Pharma Ltd. operates in the pharmaceutical industry, focusing on innovative treatments for skin diseases. The company is known for its development of a doxorubicin tip loaded dissolvable microarray needle skinpatch aimed at treating basal cell carcinoma and potentially other non-melanoma skin diseases.
YTD Price Performance: 25.51%
Average Trading Volume: 40,596
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $47.2M
For a thorough assessment of MDCX stock, go to TipRanks’ Stock Analysis page.